Journal
BLOOD
Volume 115, Issue 20, Pages 4018-4020Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-01-263624
Keywords
-
Categories
Funding
- National Institute for Health Research Biomedical Research Centre
- MRC [MC_G0802523] Funding Source: UKRI
- Medical Research Council [MC_G0802523] Funding Source: researchfish
Ask authors/readers for more resources
Outstanding results have been obtained in the treatment of chronic myeloid leukemia (CML) with first-line imatinib therapy. However, approximately 35% of patients will not obtain long-term benefit with this approach. Allogeneic hematopoietic stem cell transplantation (HCT) is a valuable second-and third-line therapy for appropriately selected patients. To identify useful prognostic indicators of transplantation outcome in postimatinib therapeutic interventions, we investigated the role of the HCT comorbidity index (HCT-CI) together with levels of C-reactive protein (CRP) before HCT in 271 patients who underwent myeloablative HCT for CML in first chronic phase. Multivariate analysis showed both an HCT-CI score higher than 0 and CRP levels higher than 9 mg/L independently predict inferior survival and increased nonrelapse mortality at 100 days after HCT. CML patients without comorbidities (HCT-CI score 0) with normal CRP levels (0-9 mg/L) may therefore be candidates for early allogeneic HCT after failing imatinib. (Blood. 2010; 115(20): 4018-4020)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available